These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23244383)

  • 1. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.
    Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
    J Am Acad Dermatol; 2013 Jan; 68(1):1.e1-9; quiz 10-12. PubMed ID: 23244383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.
    Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
    J Am Acad Dermatol; 2013 Jan; 68(1):13.e1-13; quiz 26-8. PubMed ID: 23244384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing trends in melanoma treatment and the expanding role of the dermatologist.
    Brown MD; Johnson TM; Swanson NA
    Dermatol Clin; 1991 Oct; 9(4):657-67. PubMed ID: 1934641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in melanoma therapy.
    Johnson TM; Yahanda AM; Chang AE; Fader DJ; Sondak VK
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):731-41. PubMed ID: 9591818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
    Fecher LA; Flaherty KT
    J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of melanoma.
    Brown CK; Kirkwood JM
    Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and management of high-risk and metastatic melanoma.
    Hollis G; Recio A; Schuchter L
    Semin Oncol Nurs; 2003 Feb; 19(1):32-42. PubMed ID: 12638379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-transit melanoma: an individualized approach.
    Grotz TE; Mansfield AS; Kottschade LA; Erickson LA; Otley CC; Markovic SN; Jakub JW
    Oncology (Williston Park); 2011 Dec; 25(14):1340-8. PubMed ID: 22329185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study and treatment of locally advanced melanoma].
    Moreno-Ramírez D; de la Cruz L; Ferrándiz L; Camacho FM
    Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of in-transit melanoma metastases.
    Testori A; Ribero S; Bataille V
    Eur J Surg Oncol; 2017 Mar; 43(3):544-560. PubMed ID: 27923593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in management of stage I to stage III cutaneous melanoma: a population-based study of clinical practices in France.
    Grange F; Vitry F; Granel-Brocard F; Lipsker D; Aubin F; Hédelin G; Dalac S; Truchetet F; Michel C; Batard ML; Baury B; Halna JM; Schmutz JL; Delvincourt C; Reuter G; Dalle S; Bernard P; Danzon A
    Arch Dermatol; 2008 May; 144(5):629-36. PubMed ID: 18490589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic melanoma - a review of current and future treatment options.
    Maverakis E; Cornelius LA; Bowen GM; Phan T; Patel FB; Fitzmaurice S; He Y; Burrall B; Duong C; Kloxin AM; Sultani H; Wilken R; Martinez SR; Patel F
    Acta Derm Venereol; 2015 May; 95(5):516-24. PubMed ID: 25520039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current aspects in the treatment of malignant melanoma].
    Barth A; Cerny T
    Schweiz Med Wochenschr; 1994 Sep; 124(36):1592-603. PubMed ID: 7939527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adjuvant treatment of malignant melanoma.
    Reintgen D; Kirkwood J
    J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
    Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
    J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.